Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/ijms23020771
Keywords
avermectins; selamectin; tuberculosis; Mycobacterium tuberculosis; drug repurposing
Funding
- Spanish Government (Programa de Formacion de Profesorado Universitario) [FPU18/03873]
- Slovak Research and Development Agency [APVV-19-0189]
- Italian Ministry of University and Research
- Department of Biotechnology, Chemistry and Pharmacy, University of Siena
Ask authors/readers for more resources
Avermectins, macrocyclic lactones with anthelmintic activity, have been found to be effective against Mycobacterium tuberculosis, particularly strains carrying mutations in the DprE1 gene. While biochemical assays confirmed the interaction of selamectin with DprE1, the compound may have multiple targets in inhibiting mycobacterial growth, as evidenced by discrepancies in mutant strain phenotypic assays and lipid profiles.
Avermectins are macrocyclic lactones with anthelmintic activity. Recently, they were found to be effective against Mycobacterium tuberculosis, which accounts for one third of the worldwide deaths from antimicrobial resistance. However, their anti-mycobacterial mode of action remains to be elucidated. The activity of selamectin was determined against a panel of M. tuberculosis mutants. Two strains carrying mutations in DprE1, the decaprenylphosphoryl-beta-D-ribose oxidase involved in the synthesis of mycobacterial arabinogalactan, were more susceptible to selamectin. Biochemical assays against the Mycobacterium smegmatis DprE1 protein confirmed this finding, and docking studies predicted a binding site in a loop that included Leu275. Sequence alignment revealed variants in this position among mycobacterial species, with the size and hydrophobicity of the residue correlating with their MIC values; M. smegmatis DprE1 variants carrying these point mutations validated the docking predictions. However, the correlation was not confirmed when M. smegmatis mutant strains were constructed and MIC phenotypic assays performed. Likewise, metabolic labeling of selamectin-treated M. smegmatis and M. tuberculosis cells with C-14-labeled acetate did not reveal the expected lipid profile associated with DprE1 inhibition. Together, our results confirm the in vitro interactions of selamectin and DprE1 but suggest that selamectin could be a multi-target anti-mycobacterial compound.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available